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Sialidases (SAs) and sialyltransferases (STs), the enzymes responsible for removing and
adding sialic acid to other glycans, play essential roles in viruses, bacteria, parasites, and
humans. Sialic acid is often the terminal sugar on glycans protruding from the cell surface in
humans and is an important component for recognition and cell function. Pathogens have
evolved to exploit this and use sialic acid to either “cloak” themselves, ensuring they remain
undetected, or as a mechanism to enable release of virus progeny. The development of
inhibitors against SAs and STs therefore provides the opportunity to target a range of
diseases. Inhibitors targeting viral, bacterial, or parasitic enzymes can directly target their
pathogenicity in humans. Excellent examples of this can be found with the anti-influenza
drugs Zanamivir (Relenza™, GlaxoSmithKline) and Oseltamivir (Tamiflu™, Roche and
Gilead), which have been used in the clinic for over two decades. However, the
development of resistance against these drugs means there is an ongoing need for
novel potent and specific inhibitors. Humans possess 20 STs and four SAs that play
essential roles in cellular function, but have also been implicated in cancer progression, as
glycans on many cancer cells are found to be hyper-sialylated. Whilst much remains
unknown about how STs function in relation to disease, it is clear that specific inhibitors of
them can serve both as tools to gain a better understanding of their activity and form the
basis for development of anti-cancer drugs. Here we review the recent developments in
the design of SA and ST inhibitors against pathogens and humans.
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INTRODUCTION
Sialic acid is a ubiquitous carbohydrate utilized by species across the domains of life and viruses.
Sialidases (SAs) and sialyltransferases (STs) (Figure 1A) are the carbohydrate processing enzymes
responsible for catalysing the addition and removal of sialic acid (Neu5Ac, 1) to or from glycans
attached to proteins or lipids on the cell surface. Inhibition of these enzymes is important to gain a
better understanding of the biological roles played by glycans, but is also fundamental in the
treatment of diseases. A number of these inhibitors were discovered several decades ago and are in
clinical use, whereas others are only now being realised.
The discovery of SA inhibitors has proven vital for targeting influenza, which has
historically been responsible for devastating global pandemics. Even today, influenza
accounts for between 300,000–650,000 deaths and costs the global economy billions of
dollars every year (Putri et al., 2018; WHO, 2018). Almost 30 years after the first
influenza SA inhibitors were discovered in the 1960s, an X-ray crystal structure of
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influenza SA with an inhibitor bound was solved (Edmond
et al., 1966; Varghese et al., 1992). This structure provided an
essential scaffold on which the following structure-based
drug design would be built. A wealth of papers attempting
to design drugs targeting influenza SA have been published
since, with many successes.
FIGURE 1 | (A) Reactions catalysed by SAs, trans-SAs, and STs, with glycosidic bonds broken or formed shown in red between each monosaccharide. SAs and
STs act to hydrolyse or create different linkages (α-2,3/α-2,6/α-2,8/α-2,9) between the monosaccharides, depending on the specific enzyme, while the trans-SA of the
Trypanosoma family specifically acts on α-2,3 linked sialic acids (B) Alignment of four SAs (Influenza N1, C. perfringens NanI, T. cruzi trans-SA, H. sapiens NEU2)
displaying the β-propeller structure with approximate six-fold symmetry highlighted in rainbow colours. The trans-SA transfer domain is shown in white. The active
site is enlarged, showing oseltamivir bound in the active site. The highly conserved position of active site residues of Influenza (yellow), C. perfringens (orange), T. cruzi
(red), and Human (blue) NAs, with corresponding numbering from influenza N1 (PDB IDs 3CL0, 5TSP, 2AH2, and 1VCU, respectively) (Amaya et al., 2004; Chavas et al.,
2005; Collins et al., 2008; Lee et al., 2017) (C) Alignment of three human STs (ST3-GalNAcII, ST6-Gal-I, and ST8-SiaIII) displaying the conserved Rossman β-sheet
architecture common to all STs (rainbow coloured) (PDB IDs: 6APL, 6QVT, and 5BO6, respectively). The active site is enlarged, showing CMP-Neu5Ac bound (Volkers
et al., 2015; Moremen et al., 2018; Harrus et al., 2020). Figures created using PyMOL and ChemDraw.
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FIGURE 2 | (A) Sialic acid- and Neu5Ac2en-derived inhibitors of SAs and (B) CMP-Neu5Ac-derived inhibitors of STs discussed in the text. Colours surrounding
each compound represent the organism they inhibit (see key); note that compounds 6, 13, 14, and 15 inhibit more than one organism and so both representative colours
are shown. Individual substituents on the Neu5Ac or Neu5ac2en ring are colour coded to highlight changes to the scaffold.
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However, SAs are not only encoded in viral genomes; they are
also present in bacteria and many vertebrates including
mammals. Whilst these enzymes have been explored less than
their viral counterparts, it is evident that there are opportunities
for new applications involving SA inhibitors. For example,
Clostridium perfringens (the causative agent of gangrene) uses
three SAs to aid its pathogenicity. The human parasite
Trypanosoma cruzi uses a trans-SA as a major virulence factor
to disguise it from host defences in Chagas disease.
SAs and their ST counterparts present in mammals, including
humans, have opposing roles in diseases such as diabetes, cancer
and atherosclerosis. All SAs share a strikingly similar β-propeller
architecture composed of antiparallel β-sheets in an approximate
six-fold symmetry, despite their low primary structure sequence
identity (< 26%). However, SAs all possess a conserved arginine
triad and catalytic tyrosine residue in the active site (Figure 1B).
STs display a conserved Rossman fold, as is typical of many
glycosyltransferases (Audry et al., 2011) (Figure 1C).
The design of inhibitors against these enzymes, both based on
the sialic acid scaffold and other small molecule inhibitors, is key
for the development of novel therapies and potent antibiotics,
antivirals, and antiparasitic drugs. This review will aim to
showcase the recent progress in design and discovery of such
inhibitors, with a focus on inhibitors with a sialic acid-like
scaffold, and will highlight new avenues for potential future
research.
Viral Sialidase Inhibitors
It should be noted that several viruses of the Paramyxodivirdae
family, such as Newcastle disease virus, Parainfluenza viruses,
Mumps virus, and Sendai virus, encode a haemagglutinin-
sialidase protein, however this review will only consider the
Orthomyxoviridae influenza virus SA (Taylor, 1996). It should
also be noted that only one example of a viral ST exists in the
literature: a myxoma virus ST3-Gal-I, which has not been
extensively studied (Jackson et al., 1999; Sugiarto et al., 2011).
Influenza strains are identified by the homotetrameric SA type on
their surface (groups N1-N9) and employ SAs to release new viral
particles from infected cells by cleaving the host surface sialic acid
(Itzstein, 2007). The structures of influenza SA [which belongs to
glycoside hydrolase (GH) family 34 in the CAZy database
(Lombard et al., 2014)], in complex with Neu5Ac (1) and with
Neu5Ac2en (2), a potent inhibitor with a double bond in the
pyranose ring, were reported in 1992 (Meindl et al., 1974;
Varghese et al., 1992). The Neu5Ac2en scaffold (Figure 2A),
which derives its potency by mimicking the oxocarbenium ion-
like transition state, was used in the structure-based drug design
of two anti-influenza drugs: oseltamivir (Tamiflu™, Roche and
Gilead) and zanamivir (Relenza™, GlaxoSmithKline) (3 and 4)
(Itzstein et al., 1993; Kim et al., 1997). Building on their success,
peramivir (5), another potent influenza SA inhibitor, was
designed using computational structure-based methods (Babu
et al., 2000). Each of these drugs form extensive contacts with
conserved residues in the SA active site, which out-compete
terminal sialic acid residues on the host glycans, thus
inhibiting the release of virus progeny from infected cells. Due
to viral resistance against oseltamivir, peramivir was authorized
by the FDA for emergency use in the swine flu pandemic of 2009
and was fully approved in 2014 (Thorlund et al., 2011; Wester
et al., 2016). Peramivir highlighted two important requirements
for designing Neu5Ac2en-related inhibitors; firstly the sugar ring
conformation and secondly, the position of the attached groups to
maximize binding in four conserved pockets (Babu et al., 2000).
Peramivir contains an unusual 5-membered ring but retains high
potency as its functional groups bind in a similar way to
oseltamivir and zanamivir. Due to the rapid mutation rate of
influenza, a plethora of mutant influenza subtypes are becoming
increasingly resistant to the clinically available drugs (Hussain
et al., 2017). The ever-present threat of an influenza pandemic is
of particular concern and highlights the need for pre-emptive and
effective novel inhibitor design.
More recent work by Vavricka and colleagues aimed to
characterize the mechanism employed by SAs in hydrolysis of
the glycosidic bond in order to design covalent inhibitors
(Vavricka et al., 2013). 1H NMR and structural data of the
Tyr406Asp mutant of Influenza N2 implicated Tyr406 as the
catalytic nucleophile. The addition of fluorine at C2 and C3 of
sialic acid allowed formation of a covalent adduct with the
hydroxyl group of Tyr406, providing the first covalent SA
inhibitor, 2α,3ax-difluoro-Neu5Ac (6) (Vavricka et al., 2013).
Two groups independently reported compounds with
sulphonate modifications to Neu5Ac displaying micromolar
potency against viral SAs (Hadházi et al., 2017; Vavricka et al.,
2017). The samemodification was applied to zanamivir, replacing
the carboxyl group, which enabled interactions with the
conserved Arg triad, and resulted in low-nanomolar potency
against Influenza SA (Hadházi et al., 2018). Although
“α−sulphonozanamivir” (7) is not more potent than zanamivir
against influenza SA, it is more selective, with approximately 20-
fold lower inhibition of human SA.
Zanamivir is not the only approved drug to have been
modified; oseltamivir has also been modified, with the aim of
designing compounds with higher potency than oseltamivir itself,
whilst limiting the likelihood of resistance developing. Addition
at oseltamivir’s C1, aiming to target the 430-loop (an unused
cavity of influenza SA that could accommodate potential new
drug interactions), has yielded an amide-linked carboxylate with
comparable in vivo efficacy to oseltamivir (8) (Ju et al., 2018). One
novel and innovative modification sees a 32 Å polyglycol addition
linking two oseltamivir monomers, forming “Divalent
oseltamivir” (9). The cross-linking effect allows the occupancy
of more than one SA active site in the tetramer and translates to a
68-fold increase in inhibitory potency in vitro compared to
oseltamivir (Yan et al., 2019). This strategy is currently being
explored as an exciting method of increasing drug potency and
selectivity (as mammalian SAs are not tetrameric), breathing new
life into compounds that are prone to resistance.
Bacterial Sialidase and Sialyltransferase
Inhibitors
Multiple pathogenic bacterial species, including Vibrio cholera,
Corynebacterium diptheriae, and Streptococcus pneumoniae,
utilize SAs for pathogenicity (Severi et al., 2007). However,
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Clostridium perfringens SAs (NanI, NanJ, and NanH) are
probably the best studied and understood (Corfield, 1992). C.
perfringens is pathogenic to humans and livestock, causing
gangrene, necrotizing enteritis, and food poisoning, with
disastrous health and economic implications throughout the
world (Freedman et al., 2016).
The hydrolysis of host cell sialic acids by SAs from C.
perfringens is key to its virulence and is thought to play roles
in pathogenesis, including destruction of the intestinal cell
barriers (Cioffi et al., 2012), promoting adhesion to the cell
wall by reduction of negative charges (Li et al., 2011; Lewis
and Lewis, 2012; Li and McClane, 2014) and using the sugars
in metabolism to out-compete other bacteria (Corfield, 1992).
The final and perhaps most vital function of the C. perfringens
SAs is the ability to potentiate C. perfringens toxins, however the
mechanism of this is unclear (Li et al., 2015a; Theoret et al., 2018).
Interestingly, the three SAs, NanI, NanJ, and NanH (which all
belong to family GH33 in the CAZy database), act synergistically
on the hydrolysis of complex sialic acid-containing glycans, with
substrate specificities of α-2,3, α-2,6, and α-2,8 linked sialic acids,
respectively (Li andMcClane, 2018). Neu5Ac2en has been used as
the template for designing inhibitors against C. perfringens and V.
cholera. This included an azido group modification at the C9 or
C5 position to increase selectivity for bacterial over human SAs
(10) (Khedri et al., 2012). These compounds displayed weak
inhibition, but were improved in more recent work combining
the aforementioned C2, C3-difluoro additions to produce a
covalent inhibitor (11) (Li et al., 2019). Conjugation of a small
peptide (1-4 residues) to the C9 position of Neu5Ac2en via a
triazole linkage has been attempted and showed high selectivity
for V. cholerae SA, with low micromolar IC50 values (12) (Slack
et al., 2018).
S. pneumoniae expresses two SAs, NanA, and NanB (again
family GH33), both of which have been implicated in a synergistic
relationship during coinfection with influenza, potentiating, and
exacerbating the effects of severe respiratory illness (McCullers
and Rehg, 2002; Walther et al., 2016). This motivated
investigation into the susceptibility of the bacterial SAs to the
drugs oseltamivir and zanamivir, as well as two non-carbohydrate
scaffold inhibitors, artocarpin, and katsumadain A (Walther
et al., 2016). Only the non-carbohydrate inhibitors had the
ability to inhibit both influenza and S. pneumoniae SAs,
enabling disruption of this synergism. Other non-carbohydrate
scaffolds including a Curcumin derivative, Diplacone (a naturally
occurring flavanoid), and the commonly used buffering agent 2-
CHES, have also been explored as compounds with potential
inhibitory activity toward bacterial SAs (Lee et al., 2014; Lee et al.,
2017; Kim and Park, 2018). The aforementioned α-sulphonate
modifications to the anomeric carbon of Neu5Ac have also been
shown to be effective against both S. pneumoniae and C.
perfringens SAs (13) (Vavricka et al., 2017).
A handful of pathogenic bacteria express STs as virulence
factors to produce molecular mimics of mammalian glycans, thus
evading the host immune system by adding terminal sialic acid
residues to their lipooligosccharides. For example, two pathogens
of the genus Neisseria (N. meningitidis and N. gonorrhoeae)
encode crucial poly-STs (family GT38) that adds α-2,8 and
α-2,9 linked sialic acid chains to the extracellular capsule of
these Gram-negative bacteria, mimicking mammalian poly
sialic acid glycans (Bhattacharjee et al., 1975). N. meningitidis
synthesizes Neu5Ac de novo, whereas N. gonorrhoeae scavenges
the mammalian nucleotide sugar donor (Smith et al., 1995; Vogel
et al., 1996). Haemophilus influenzae uses an α-2,3 ST which is
essential for virulence in otitis media infections (Bouchet et al.,
2003). Several groups have published structures of Campylobacter
jejuni and Pasturella multocida STs, among other prokaryotes,
however limited examples exist of inhibitor design against
bacterial STs (Figure 2B) (Chiu et al., 2007; Ni et al., 2007).
The general purpose ST inhibitor CMP-3Fax-Neu5Ac (CMP-
Neu5Ac with an axial fluorine at C3 of sialic acid) (14)
displays moderate inhibitory strength toward bacterial STs,
with a Ki of ∼25 µM (Ni et al., 2007). Kumar et al. attempted
to discard the scissile phosphate in favour of a selection of
uncharged amide-, sulphonamide- and triazole-linked
compounds, incorporating Neu5Ac, Neu5Ac2en and
substituted benzene moieties. Unfortunately, these compounds
all displayed relatively low inhibition. Swapping Neu5Ac for a
benzene group has also been integrated in the design of
fluorescent probes targeting STs, with several of these probes
achieving nanomolar inhibition against P. multocida ST,
including the non-fluorescent precursor scaffold (15) (Preidl
et al., 2014).
Trypanosome Trans-Sialidase Inhibitors
Parasitic protozoans of the Trypanosoma genus are responsible
for extremely debilitating and life-threatening illnesses—African
sleeping sickness and Chagas disease—for millions of people in
less economically developed countries (World Health
Organisation, 2020a; World Health Organisation, 2020b).
These single-celled organisms spread through the bite of an
insect vector and result in circulation of the parasite in the
host’s blood (Radwanska et al., 2018). Ordinarily, such foreign
material would be suppressed by the immune system, however,
trypanosomes encode a crucial virulence factor (a trans-SA,
belonging to family GH33) which is partly responsible for
evasion from this system (Nardy et al., 2016). This enzyme is
a glycoside hydrolase; however, the enzyme promotes
nucleophilic attack by a glycan rather than a water molecule,
and thus acts as a synthetic enzyme. The trans-SA cleaves sialic
acids from host cells and covalently attaches them to terminal
β-galactose acceptor molecules on the surface of the parasite,
effectively masking itself in pseudo-host tissue. The inability to
clear this parasite results in the establishment of chronic
infection. The absence of a trans-SA in humans has
established it as a promising drug target.
It is advantageous to target both the donor and acceptor sites
of the trans-SA to ensure inhibition (Buschiazzo et al., 2002). To
this end, a group of unusual triazole linked sialic acid and
galactose disaccharides were devised in one study, resulting in
a lead compound with µM potency against T. cruzi trans-SA (16)
(Campo et al., 2012). More recently, multivalent sugar syntheses
were attempted to find new trypanosome trans-SA inhibitors,
with the most successful compound (17, a tetra-sialic acid
conjugate) exhibiting 99% inhibition at 1 mM and an IC50 of
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450 µM (Figueredo et al., 2019). Unfortunately, the inclusion of
multiple sugars is likely to give poor absorbance and low
bioavailability, highlighting the need for further research.
A wealth of other non-Neu5Ac-derived inhibitors have been
designed and discovered recently which target the trans-SA. This
included a search of 3180 FDA approved drugs with hopes for
repurposing, benzyl β-lactoside analogues and a fragment-based
screening approach based on aryl propionic acid (Lara-Ramirez
et al., 2017; Kashif et al., 2018; Morrone-Pozzuto et al., 2019). One
particular notable compound is a pthaloyl derivative with a
predicted Kd of 7.2 nM (Neu5Ac2en has a predicted Kd of
1.9 µM) and close to 90% trypanocidal activity, which is
comparable with current drugs on the market. This compound
is predicted by virtual screening to use the naphthalene and
indoline rings to make extensive contacts with surrounding
hydrophobic residues in the active site, although this needs to
be validated experimentally (Kashif et al., 2018).
Human Sialidase and Sialyltransferase
Inhibitors
In the body, STs and SAs are responsible for the addition and
removal of sialic acids, respectively, from the termini of glycans
presented on the surface of cells. The equilibrium between the
opposing roles of these enzymes allows remodelling of the
extracellular glycans and is important in many diseases
(Pearce and Heinz, 2015). Four SA isozymes are encoded in
the human genome termed NEU1—4 (belonging to family
GH33), which differ in cellular expression and localization
(Lipničanová et al., 2020). Unfortunately, NEU2 is the only
human SA with its structure solved, due to the inability to
grow adequate crystals of the membrane bound NEU1, 3, and
4 (Chavas et al., 2005). The roles of these SAs have been
implicated in various studies to be important in cancer,
atherosclerosis, diabetes, and neurodegenerative diseases (Dridi
et al., 2013; Shiga et al., 2015; Zhang et al., 2019). For example,
NEU3 has been implicated in the hydrolysis of sialic acid from
GM3 (a common sialic acid-containing glycosphingolipid). This
desialylation allows GM3 to become a ligand for the EGFR
receptor and increases ERK and AKT phosphorylation, all of
which have strong links to various cancers and tumorigenesis
(Bonardi et al., 2014; Mozzi et al., 2015). Excessive sialylation
caused by deficient levels of NEU1 may cause abnormal
accumulation of amyloid precursor protein, which is known to
initiate the formation of fibrils and plaques of Amyloid β (Aβ)
and Tau proteins in Alzheimer’s disease (Annunziata et al., 2013).
Furthermore, the accumulation of Aβ and Tau fibrils has recently
been linked to increased desialylation of microglial cells, leading
to enhanced phagocytosis of healthy neurons and further
propagates the negative effects on memory (Allendorf et al.,
2020; Puigdellívol et al., 2020). Minami et al. showed that the
upregulation of SA activity improves hippocampal memory
processing, which may provide a potential treatment for
neurodegenerative diseases (Minami et al., 2017).
Although many of the aforementioned inhibitors targeting
pathogens display weak inhibition of the human SAs, the lack of
potent and highly specific inhibitors to aid research has hindered
further progress in understanding the roles played by SAs in
diseases. The most promising recent efforts to produce a human
SA inhibitor built on previous work involving modification of
Neu5Ac2en at C9 (Albohy et al., 2013). The best compound
included a large biaryl moiety linked by a triazole at C9 of
Neu5Ac2en (18), which conferred 15-fold higher selectivity for
human NEU3 than the compound with just the triazole alone,
and had a high nanomolar IC50 value (Guo et al., 2018a). The
same group has also recently developed highly selective NEU1
and NEU2 inhibitors with a range of C4, C5, and C9 additions
(Guo et al., 2018b). To date, these compounds represent the best
tools available for research to elucidate the roles of human SAs in
disease.
Humans also express 20 different, but evolutionarily related,
STs, separated into three classes based on the position of the
linkage between sialic acid and the rest of the glycan (α-2,3, α-2,6,
or α-2,8; all belong to family GT29) (Tsuji et al., 1996; Harduin-
Lepers, 2010; Lombard et al., 2014) Altered cell sialylation and
upregulation of STs have been observed in many cancers and the
development of metastases, including oral (Vajaria et al., 2018),
liver (Dall’Olio et al., 2004), breast (Picco et al., 2010), stomach
(Cebi et al., 2016), cervical (López-Morales et al., 2009) and
ovarian cancers (Wang et al., 2005), among others. Using a
genome-wide association study, downregulation of a
polysialyltransferase (ST8-Sia-II) was found to be a potential
susceptibility gene for several mental illnesses such as bipolar
disorder and schizophrenia (McAuley et al., 2012). ST6-Gal-I has
been heavily studied in relation to cancer [reviewed recently by
Garnham et al. (2019)], with multiple studies correlating its
expression to increased aggressiveness of tumours and
metastases. In one instance, the death receptor Fas, which
plays a key role in apoptosis, was found to be a target of
abnormal sialylation by ST6-Gal-I. This appeared to
downregulate the apoptotic effects of Fas, resulting in
diminished activation of caspases 3 and 8, thus contributing to
the “Resisting Cell Death” hallmark of cancer (Hanahan and
Weinberg, 2000; Swindall and Bellis, 2011). Furthermore, the
heightened tumour cell surface sialylation is an important
characteristic of resistance to certain cytotoxic anti-cancer
drugs (vincristine and nilotinib), suggesting that inhibition of
sialyltransferases may be an effective method of re-sensitizing
cancerous cells to such drugs (Parameswaran et al., 2013).
Only a handful of human ST structures exist, due to difficulties
successfully crystallizing these enzymes, as they are often
membrane bound proteins. The first ST structure was reported
in 2013 (Kuhn et al., 2013; Volkers et al., 2015; Harrus et al.,
2020). This has no doubt hindered the structure-based design of
potent ST inhibitors when compared to the viral SA inhibitors.
Human ST inhibitors that mimic the natural substrate are
composed of three components which may be modified: the
cytosine base, phosphate and sialic acid. The general-purpose
ST inhibitor CMP-3Fax-Neu5Ac (15) displays a Ki in the low µM
range against hST6-Gal-I (the most studied and targeted human
ST) (Burkart et al., 2000). Skropeta and Yu’s research group have
improved this drastically, publishing several papers recently to
highlight tighter binding inhibitors. Many of these included
α-hydroxyphosphonates in place of the carboxyl C1 as
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transition state analogue mimics, with later compounds also
including uncharged carbamate and triazole linkers to improve
potential pharmacokinetic properties (Skropeta et al., 2004;
Montgomery et al., 2016; Montgomery et al., 2017). The most
recent inhibitors designed by this group incorporate a benzene
scaffold in place of the sialic acid (similar to the bacterial ST
inhibitors) and also exchange the cytosine for a 5′-deoxy-uridine
ring (19). The current lead compound from this group is a
phenoxy-substituted compound (20) with a 19 nM Ki value
against hST6-Gal-I. Other groups have also developed potent
inhibitors of hST6-Gal-I, with simple benzene amide linked
compounds intending to mimic the double bond character of
the oxocarbenium transition state (21, Ki  16 nM), cyclopentane
scaffold compounds in place of the sialic acid, similar to
peramivir (22, Ki  28 nM), and the aforementioned
fluorescent probe (23, Ki  9 nM) (Li et al., 2015b ; Preidl
et al., 2014; Guo et al., 2017).
Alternative methods of inhibition have been explored such as
bisubstrate inhibitors (which aim to mimic the product of the ST
by incorporating two or more sugars linked by thioethers or a
phosphate), swapping the cytosine for 5-fluoro uracil or adenine,
or modifying the cytosine with amethyl group (Hinou et al., 2002;
Nakahara et al., 2004; Izumi et al., 2005; Lee et al., 2006; Miyazaki
et al., 2008). A major hurdle with many glycosyltransferase
inhibitors is their poor adherence to criteria for a drug
candidate, with a high molecular weight, an excessive number
of hydrogen bond donors/acceptors and sometimes the presence
of a negative charge (Lipinski, 2004). Metabolic inhibitors of STs
offer a promising solution, hijacking the cell’s usual synthetic
routes to create the desired inhibitors in vivo, thus bypassing the
need to sacrifice potency for adequate pharmacokinetic
properties. However, further research is necessary to validate
this method and assess the selectivity of the inhibitors for a
particular enzyme (Rillahan et al., 2012). It should also be noted
that the inhibition of ST8-Sia-III in the brain of mice impairs
their procedural long-term memory, so characterizing the
specificities of inhibitors targeting STs should be a future area
of research (Rinflerch et al., 2013).
Although beyond the scope of this review, there are
natural products, or natural product-like, compounds that
inhibit SAs and STs. For example, soybean derived
soyasaponin has been shown to inhibit cancer metastasis
in vivo, which inspired the synthesis of lithocholic acid
analogues. One cell permeable analogue attenuated α-2,3-
sialylation on cell surface glycans, and was demonstrated to
suppress metastasis of lung cancer cells by inhibiting
modification of integrin-β1, thus impacting the FAK/
paxillin/Rho signalling pathways (Chen et al., 2011). A
more extensive review of other classes of ST inhibitors can
be found in an article by Wang et al. (2016).
CONCLUDING REMARKS
This review has displayed the breadth of novel SA and ST
inhibitors currently being developed, particularly highlighting
the recent iterative successes of using the Neu5Ac2en and
Neu5Ac frameworks for new inhibitor design and concepts.
The presence of SAs and STs across the domains of life and
viruses highlights the need for selective and potent compounds.
Structural, mechanistic, and computational information is
essential to guide this design process. Several challenges exist
for ST inhibition: not only in obtaining protein for the necessary
in vitro studies, but also if incorporation of a negative charge and
several polar groups in CMP-sialic acid mimics will be conducive
to cell uptake and oral bioavailability. The critical roles that STs
play in the progression of some human cancers, however, means
research in this area is of great importance. Whilst there have
been drugs in the clinic targeting viral SAs for over 2 decades, the
need for new inhibitors is critical due to the ever-looming threats
of pathogenic resistance and pandemics. The improvement of
existing compounds presented here, and success in the design of
novel compounds, will ensure preparedness in the face of these
future challenges.
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